<DOC>
	<DOCNO>NCT00038623</DOCNO>
	<brief_summary>Study Yttrium-ibritumomab ( Zevalin ) For treatment Patients Relapsed &amp; Refractory Mantle Cell Lymphoma</brief_summary>
	<brief_title>Study Of Yttrium-ibritumomab ( Zevalin ) For Treatment Of Patients With Relapsed And Refractory Mantle Cell Lymphoma</brief_title>
	<detailed_description>Mantle cell lymphoma cell express protein call CD20 . Ibritumomab tiuxetan antibody target CD20 , carry radioactive material call 90-Yttrium . The radioactivity deliver cancer cell antibody help kill mantle cell lymphoma cell . Before treatment start , patient physical exam , include blood urine test . Patients chest x-ray CT scan abdomen pelvis . Bone marrow sample take large needle . A cardiogram ( EKG ) perform therapy 1 3 month therapy . Patients study receive one dose rituximab vein 6 8 hour first day treatment . This follow infusion antibody label radioactive indium , allow image tumor site normal tissue site bind antibody . Imaging perform twice nuclear medicine department Day 1 , either Day 2 3 . On day 8 ( 7 day first dose rituximab ) , patient receive second dose rituximab . This immediately follow dose Ibritumomab tiuxetan give vein ten minute . Patients receive diphenhydramine ( Benadryl ) vein mouth acetaminophen ( Tylenol ) mouth dose rituximab . This do prevent fever chill . All treatment give outpatient setting . Blood test take weekly first 3 month , every 3 month 1 year , every 6 month 3 year . CT scan , x-ray , bone marrow biopsy repeat needed 3 month therapy every 3 month 1 year , every 6 month 3 year . If tumor shrink 3 month therapy increase size , patient offer different treatment . This investigational study . Up 35 patient take part study . All enrol M. D. Anderson .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Mantle-Cell</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>1 . Histologically confirm , relapse refractory mantle cell lymphoma require treatment . 2 . No anticancer therapy three week ( 6 week rituximab , nitrosurea , Mitomycin C ) prior study initiation , fully recover toxicity associate prior surgery , radiation treatment , chemotherapy , immunotherapy . 3 . An IRBapproved sign informed consent . 4 . Age great equal 18 year . 5 . Expected survival great equal 3 month . 6 . Prestudy performance status 0 , 1 , 2 accord World Health Organizations ( WHO ) criterion . 7 . Acceptable hematologic status within two week prior patient registration , include : Absolute neutrophil count ( segment neutrophils = band * total White Blood Count ( WBC ) ) great equal 1,500/mm^3 ; Platelets great equal 1000,000/mm^3 . 8 . Female patient pregnant lactate . 9 . Men woman reproductive potential following accept birth control method ( determine treat physician , however abstinence acceptable method ) . 10 . Patients previously investigational Phase II anticancer drug longterm toxicity expect , patient drug eight week significant post treatment toxicity observe . 11 . Patients determine less 25 % bone marrow involvement mantle cell lymphoma within six week registration . Measurement determine bilateral bone marrow biopsy . This criterion must strictly meet adequate patient safety . 1 . Prior autologous allogeneic bone marrow transplantation ( ABMT ) peripheral blood stem cell ( PBSC ) rescue therapy . 2 . Prior radioimmunotherapy . 3 . Presence Central Nervous System ( CNS ) lymphoma . 4 . Patients HIV AIDSrelated lymphoma . 5 . Patients pleural effusion . 6 . Patients abnormal liver function : Total bilirubin great 2.0mg/dL 7 . Patients abnormal renal function : serum creatinine great 2.0mg/dL 8 . Patients receive prior external beam radiotherapy great 25 % active bone ( involved field regional ) . 9 . Patients receive Granulocyte colonystimulating factor ( GCSF GMCSF ) therapy within two week prior treatment . 10 . Serious nonmalignant disease infection , opinion investigator and/or sponsor , would compromise protocol objective . 11 . Major surgery , diagnostic surgery , within four week . 12 . Impaired bone marrow reserve indicate one following : ) History fail stem cell collection . b ) Platelet count le 1000,000 cells/mm^3 . c ) Hypocellular bone marrow ( le 15 % cellularity ) . ) Marked reduction bone marrow precursor one cell line ( granulocytic , megakaryocytic , erythroid ) . 13 . Presence leukemic phase disease define peripheral blood absolute lymphocyte count great 5,000/microliters .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2011</verification_date>
	<keyword>Relapsed/Refractory Mantle Cell Lymphoma</keyword>
	<keyword>Yttrium-Ibritumomab</keyword>
	<keyword>Zevalin</keyword>
</DOC>